Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
BPC-157 Arginate (Stable Form)
BPC-157 Arginine Salt, BPC-157-Arg
The arginine salt form of BPC-157, developed to improve stability and shelf life compared to the standard acetate salt. BPC-157 arginate maintains the same gastric pentadecapeptide sequence but uses arginine as the counter-ion, which provides better stability at room temperature and in solution. This form is increasingly preferred by compounding pharmacies and researchers.
A synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice. One of the most widely researched peptides for tissue repair and recovery.
Same mechanism as standard BPC-157 — upregulates growth factor expression (VEGF, FGF, EGF), promotes angiogenesis, modulates nitric oxide pathways, and interacts with the dopaminergic system. The arginine counter-ion does not change the peptide's pharmacological activity but improves chemical stability, particularly in aqueous solution.
BPC-157 promotes angiogenesis (new blood vessel formation), upregulates growth factor expression, and modulates nitric oxide synthesis. It appears to accelerate healing of tendons, ligaments, muscles, and the GI tract through multiple pathways including the FAK-paxillin pathway.
- Gut healing and GI repair
- Tendon and ligament recovery
- Muscle injury repair
- Neuroprotection
- Stable alternative to BPC-157 acetate
- Tendon and ligament repair
- Gut healing and GI protection
- Muscle injury recovery
- Joint health
- Post-surgical recovery
- Same risk profile as standard BPC-157
- No FDA-approved human trials
- Theoretical concerns about growth factor upregulation
- Quality varies between sources
- Limited human clinical trial data
- Most research is animal-based
- Potential interactions with blood pressure medications
- Injection site reactions
- Long-term safety profile unknown
Same regulatory status as BPC-157. Removed from Category 2 on April 15, 2026. Scheduled for PCAC review on July 23, 2026 (Day 1). The arginate form is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.
PCAC: July 23, 2026
On April 15, 2026, the FDA announced BPC-157 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. It is now scheduled for formal PCAC (Pharmacy Compounding Advisory Committee) review on July 23, 2026, to determine whether it should be added to the 503A bulk drug substances list. Removal from Category 2 does not authorize compounding — pharmacies should exercise caution until PCAC issues its recommendation. Previously reclassified to Category 1 in February 2026, a step that is now superseded by this more formal process.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.